LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Stock List・Danaher Corp

Search

Danaher Corp

Closed

SectorHealthcare

178.47 1.79

Overview

Share price change

24h

Current

Min

173.53

Max

178.47

Key metrics
By Trading Economics
Income	-168M 1B
Sales	-887M 6B
P/E Sector Avg	34.859 49.888
EPS	2.06
Dividend yield	0.74
Profit margin	17.291
Employees	58,000
EBITDA	-514M 1.5B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.42% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.74% 2.38%
Next Earnings	21 Jul 2026
Next Dividend date	31 Jul 2026
Next Ex Dividend date	26 Jun 2026

Market Stats
By TradingEconomics
Market Cap	-11B 127B
Previous open	176.68
Previous close	178.47

News Sentiment

By Acuity

17%

83%

34 / 344 Healthcare

Danaher Corp Chart

Past performance is not a reliable indicator of future results.

Related News

21 Apr 2026, 11:36 UTC

Earnings

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21 Apr 2026, 11:00 UTC

Earnings

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21 Apr 2026, 10:06 UTC

Earnings

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21 Apr 2026, 10:05 UTC

Earnings

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21 Apr 2026, 10:05 UTC

Earnings

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21 Apr 2026, 10:05 UTC

Earnings

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21 Apr 2026, 10:04 UTC

Earnings

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21 Apr 2026, 10:04 UTC

Earnings

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21 Apr 2026, 10:00 UTC

Earnings

Danaher 1Q Cont Ops EPS $1.45 >DHR

21 Apr 2026, 10:00 UTC

Earnings

Danaher 1Q Adj EPS $2.06 >DHR

21 Apr 2026, 10:00 UTC

Earnings

Danaher 1Q Sales $5.95B >DHR

21 Apr 2026, 10:00 UTC

Earnings

Danaher 1Q EPS $1.45 >DHR

21 Apr 2026, 10:00 UTC

Earnings

Danaher 1Q Net $1.03B >DHR

17 Apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 Apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 Feb 2026, 20:06 UTC

Acquisitions, Mergers, Takeovers

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17 Feb 2026, 15:14 UTC

Acquisitions, Mergers, Takeovers

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17 Feb 2026, 14:39 UTC

Acquisitions, Mergers, Takeovers

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 Feb 2026, 13:30 UTC

Acquisitions, Mergers, Takeovers

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 Feb 2026, 13:15 UTC

Acquisitions, Mergers, Takeovers

Danaher Strikes $10 Billion Deal for Masimo -- Update

17 Feb 2026, 13:03 UTC

Acquisitions, Mergers, Takeovers

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17 Feb 2026, 13:03 UTC

Acquisitions, Mergers, Takeovers

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17 Feb 2026, 13:02 UTC

Acquisitions, Mergers, Takeovers

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17 Feb 2026, 13:02 UTC

Acquisitions, Mergers, Takeovers

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17 Feb 2026, 13:02 UTC

Acquisitions, Mergers, Takeovers

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17 Feb 2026, 13:01 UTC

Acquisitions, Mergers, Takeovers

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17 Feb 2026, 13:00 UTC

Acquisitions, Mergers, Takeovers

Danaher to Buy Masimo for $180/Share >DHR MASI

17 Feb 2026, 13:00 UTC

Acquisitions, Mergers, Takeovers

Danaher To Acquire Masimo Corporation >DHR MASI

17 Feb 2026, 11:09 UTC

Acquisitions, Mergers, Takeovers

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17 Feb 2026, 11:09 UTC

Acquisitions, Mergers, Takeovers

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

31.42% upside

12 Months Forecast

Average 231.45 USD 31.42%

High 270 USD

Low 184.04 USD

Based on 20 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

17

Buy

3

Hold

0

Sell

Based on 20 analysts giving stock ratings to Danaher Corp - Dist in the past 3 months.

Sentiment

By Acuity

34 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,080.21

JNJ

Johnson and Johnson

223.5

ABBV

AbbVie Inc

217.16

UNH

UnitedHealth Group Inc

377.97

MRK

Merck & Co Inc.

114.86

Live chat